SCHEDULE: Ayrton Capital, Alto Fund Disclose 9.72% Stake in Genprex

Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri have disclosed a 9.72% beneficial ownership stake in Genprex, Inc. through warrants.

Summary

• Ayrton Capital LLC, Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri (collectively, the "Reporting Persons") have reported beneficial ownership of 249,788 shares of Genprex, Inc. Common Stock.
• This ownership represents 9.72% of Genprex's outstanding Common Stock.
• The reported shares are issuable upon the exercise of certain warrants held by the Reporting Persons.
• The issuable shares are subject to a 9.99% beneficial ownership blocker.
• The percentage of class is calculated based on 2,318,894 shares outstanding as of November 19, 2025, plus the 249,788 shares issuable from the warrants.
• Ayrton Capital LLC serves as the investment manager for Alto Opportunity Master Fund, and Waqas Khatri is the managing member of Ayrton Capital LLC and a director of Alto Opportunity Master Fund.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Genprex, Inc.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant institutional investment often signals confidence in the company's long-term potential, even if the filing itself is purely factual.

Positives

• A significant institutional investor, Alto Opportunity Master Fund, managed by Ayrton Capital LLC, has taken a substantial stake in Genprex, Inc., potentially signaling confidence in the company's future prospects.
• The investment is structured through warrants, which could provide future capital to Genprex upon exercise, depending on market conditions and the warrant terms.

Negatives

• The filing itself does not contain any negative financial or operational information about Genprex, Inc.

Risks

• The beneficial ownership is derived from warrants, meaning the actual shares are not yet outstanding and their exercise is subject to the terms of the warrants, including potential beneficial ownership blockers.
• A large ownership stake, even if passive, could still be perceived by some as a potential influence on the issuer, despite the certification stating otherwise.

Future Outlook

The filing does not provide any forward-looking statements or guidance from Genprex, Inc. It solely reports the beneficial ownership stake of the Reporting Persons.

Management Comments

• Waqas Khatri, Managing Member of Ayrton Capital LLC and Director of Alto Opportunity Master Fund, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Genprex, Inc.

Industry Context

StockSavvy.ai notes that the disclosure of a significant beneficial ownership stake by an investment fund like Alto Opportunity Master Fund, managed by Ayrton Capital LLC, is a common occurrence in the public markets. Such filings indicate that institutional investors are taking positions in companies, which can sometimes be interpreted as a vote of confidence. For biotechnology companies like Genprex, which often require substantial capital and have long development cycles, attracting institutional investment is crucial.

Comparison to Industry Standards

• This Schedule 13G filing is standard for reporting beneficial ownership exceeding 5% by passive investors, aligning with SEC regulations for transparency in public markets.
• The 9.72% stake is a substantial position, nearing the 10% threshold that often triggers additional regulatory scrutiny or activist investor considerations, though the filing explicitly states a passive intent.
• The use of warrants for investment is common in growth-oriented sectors like biotechnology, allowing investors to gain exposure with potential upside while managing initial capital outlay.

Stakeholder Impact

• Shareholders: The disclosure of a new significant institutional investor could be viewed positively, potentially increasing investor confidence and liquidity.
• Company Management: Awareness of a large, passive institutional holder may influence strategic decisions, though the filing states no intent to influence control.

Key Dates

Recommendation

The filing indicates a significant institutional investment in Genprex, which is generally a positive signal. However, as a Schedule 13G, it is a factual disclosure of ownership and does not provide new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. The investment through warrants suggests a long-term view, but without further company-specific news, a 'hold' recommendation is appropriate for existing investors, while potential investors should conduct further due diligence.

Keywords

Genprex, Ayrton Capital, Alto Opportunity Master Fund, Waqas Khatri, Schedule 13G, Beneficial Ownership, Warrants, Common Stock, SEC Filing, Institutional Investor